Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBV Immunological Agent with Toripalimab for EBV-LPD
NCT06666153Phase 1Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2024
- Primary completion
- Dec 2025
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EBV immunological agent in chronic active Epstein-Barr virus infection (CAEBV) and Post-Transplant Lymphoproliferative Disorder (PTLD), sponsored by West China Hospital of Sichuan University. Primary endpoint: Safety and tolerability at 12 months. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
EBV immunological agent
03
Conditions
chronic active Epstein-Barr virus infection (CAEBV)Post-Transplant Lymphoproliferative Disorder (PTLD)
Beyond the preview
Go deeper on NCT06666153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06666153.